FDA Approval Summary: Repotrectinib for Locally Advanced or Metastatic ROS1-Positive Non–Small Cell Lung CancerMichael I. Barbato, Nicole Drezner, Claudia P. Miller et al.|Clinical Cancer Research|2024Cited by 13
FDA Approval Summary: Vorasidenib for <i>IDH</i> -Mutant Grade 2 Astrocytoma or Oligodendroglioma Following SurgeryMichael I. Barbato, Nicole Drezner, Amy Barone et al.|Clinical Cancer Research|2025Cited by 9